This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation Protein Therapeutics Summit

$700 Savings Ends In:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
September 28-30, 2022
Boston Convention and Exhibition Center

Volker Schellenberger, Ph.D.
CTO at Amunix

Profile

Volker Schellenberger is President and CTO of Amunix Pharmaceuticals, which he co-founded in 2006. He initially served as Amunix’ Chief Scientific Officer and is the lead inventor of the company’s XTEN as well as XPAT platforms of protease-activated T cell engagers. Volker has over 25 years of industry experience in protein engineering and drug discovery. Prior to co-founding Amunix he served as head of Genencor’s protein engineering department.

Volker received his Ph.D. from Leipzig University (Germany) in 1986. He is author of over 40 scientific papers and inventor of more than 70 issued or pending patent applications. He is a recipient of the Karl Lohmann prize of the German Society of Biochemists.